Tags
- 3
- 4
- 6
- A
- Acquire
- Acquisition
- Acro
- Across
- Ad
- Aggression
- Allergic
- Allergic contact dermatitis
- An
- Antibodies
- Antibody
- Approved
- Approximately
- Asset
- Asthma
- Atopic dermatitis
- Atopy
- Aug
- Biotechnology
- Bispecific monoclonal antibody
- Boosts
- Candice Long
- Care
- Cell
- Clinical endpoint
- Commission
- Commitment
- Complement
- Complete
- Completion
- Contact
- Contact dermatitis
- Continuing
- Contribution
- Cutaneous condition
- D
- D5
- David Lee
- Dermatitis
- Development
- Disease
- Distinct
- Dosing
- Editor
- Editor's Note
- Eight
- Enter
- Europe
- European
- European Commission
- FDA
- Fit
- Food and Drug Administration
- Frequency
- Gain
- Global Rights
- Heavy
- Helper
- Homeostasis
- IL-13
- IL-22
- Immune
- Immune disorder
- Immunology
- Include
- Includes
- In Europe
- Infection
- Inflammation
- Inflammatory
- Innovation
- Innovation strategy
- Integration
- Intention
- Interleukin 13
- Johnson
- Johnson & Johnson
- Johnson Johnson
- Lead-in
- M
- Meanwhile
- Mediated
- Medicine
- Mergers & Acquisitions
- Milestone
- Minimum
- Moderate-to-severe
- Multiple myeloma
- Need
- Needs
- New
- Note
- Oncology
- Onset
- Originally
- Pathway
- Pathways
- Patient
- Payment
- Phase
- Phase 1
- Phase II
- Pipeline
- PLU
- Portfolio
- Pre-clinical development
- Press release
- Privately held company
- Promising
- Protection
- Psoriasis
- Publishing
- Redefine
- Reduction
- Refractory
- Regulation
- Regulatory approvals
- Relapse
- Responsibility
- Rights
- Second
- Second Half
- Six
- Skin
- Skin inflammation
- Skin protection
- Source
- Specialization
- Standard of care
- Start
- Strategic fit
- Strategy
- Stromal cell
- Strong
- Studie
- Subsidiary
- Target
- Targeting
- Targets
- Team a
- The european
- T helper cell
- The Onset
- Therapy
- The standard
- Thrilled
- Thymic stromal lymphopoietin
- Thymus
- Tissue
- Transaction
- Treating
- Two New
- V
- Variety
- Vice president
- Who
- Worldwide
- Wound
- Wound healing
- Year Three